[{"Assets_0_Q3_USD":473484000.0,"CommonStockSharesOutstanding_0_Q3_shares":19682000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":62873000.0,"NetIncomeLoss_1_Q3_USD":7036000.0,"NetIncomeLoss_3_Q3_USD":37192000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":19673000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":19549000.0,"StockholdersEquity_0_Q3_USD":448097000.0,"EarningsPerShareBasic_1_Q3_USD":0.36,"EarningsPerShareBasic_3_Q3_USD":1.9,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190809"}]